These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

82 related items for PubMed ID: 9597520

  • 1. Use of abciximab in interventional cardiology.
    Chronos N, Vahanian A, Betriu A, Emanuelsson H, Goldberg S, Gulba D, van Hout BA.
    Eur Heart J; 1998 Apr; 19 Suppl D():D31-9. PubMed ID: 9597520
    [Abstract] [Full Text] [Related]

  • 2. Use of abciximab in interventional cardiology.
    Chronos N, Vahanian A, Betriu A, Emanuelsson H, Goldberg S, Gulba D, van Hout BA.
    Am Heart J; 1998 Apr; 135(4):S67-76. PubMed ID: 9539497
    [Abstract] [Full Text] [Related]

  • 3. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes.
    Braunwald E, Maseri A, Armstrong PW, Califf RM, Gibler WB, Hamm CW, Simoons ML, Van de Werf F.
    Eur Heart J; 1998 Apr; 19 Suppl D():D22-30. PubMed ID: 9597519
    [Abstract] [Full Text] [Related]

  • 4. Safe use of platelet GP IIb/IIIa inhibitors.
    Ferguson JJ, Kereiakes DJ, Adgey AA, Fox KA, Hillegass WB, Pfisterer M, Vassanelli C.
    Eur Heart J; 1998 Apr; 19 Suppl D():D40-51. PubMed ID: 9597521
    [Abstract] [Full Text] [Related]

  • 5. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM, Califf RM, Moliterno DJ, Ellis SG, Ducas J, Kramer JH, Kleiman NS, Cohen EA, Booth JE, Sapp SK, Cabot CF, Topol EJ.
    N Engl J Med; 1999 Jul 29; 341(5):319-27. PubMed ID: 10423466
    [Abstract] [Full Text] [Related]

  • 6. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, Cohen EA, Bertrand M, Neumann FJ, Stone GW, DiBattiste PM, Demopoulos L, TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy Trial.
    N Engl J Med; 2001 Jun 21; 344(25):1888-94. PubMed ID: 11419425
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The role of glycoprotein IIb/IIIa platelet inhibition in percutaneous coronary intervention in the stent era.
    Adelman AG, Caramori PR, Cohen EA, Chisholm RJ, Côté G, Ducas J, O'Neill BJ, Tcheng JE.
    Can J Cardiol; 1998 Aug 21; 14(8):1057-66. PubMed ID: 9738165
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization: what more needs to be proven?
    Lincoff AM, Topol EJ.
    Eur Heart J; 2000 Jun 21; 21(11):863-7. PubMed ID: 10806004
    [No Abstract] [Full Text] [Related]

  • 12. A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: rationale and design of the TARGET study.
    Moliterno DJ, Topol EJ.
    Am Heart J; 2000 Nov 21; 140(5):722-6. PubMed ID: 11054616
    [Abstract] [Full Text] [Related]

  • 13. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators.
    Kleiman NS, Lincoff AM, Kereiakes DJ, Miller DP, Aguirre FV, Anderson KM, Weisman HF, Califf RM, Topol EJ.
    Circulation; 1998 May 19; 97(19):1912-20. PubMed ID: 9609084
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of the platelet glycoprotein IIb/IIIa inhibitor abciximab in Chinese patients undergoing high-risk angioplasty.
    Chen YH, Chen JW, Wu TC, Ding PY, Wang SP, Chang MS.
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jan 19; 63(1):8-15. PubMed ID: 10645045
    [Abstract] [Full Text] [Related]

  • 15. Abciximab and atherosclerotic heart disease: use in percutaneous coronary intervention, acute coronary syndromes and acute myocardial infarction.
    Gum PA, Lincoff AM.
    Int J Clin Pract; 2003 Jan 19; 57(1):43-8. PubMed ID: 12587942
    [Abstract] [Full Text] [Related]

  • 16. Clinical trials of IIb/IIIa receptor blockers in patients undergoing angioplasty.
    Mathew TP, Adgey AA.
    Semin Interv Cardiol; 1999 Jun 19; 4(2):67-75. PubMed ID: 10473875
    [Abstract] [Full Text] [Related]

  • 17. Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results.
    Popma JJ, Satler LF.
    J Invasive Cardiol; 1994 Jun 19; 6 Suppl A():19A-28A; discussion 45A-50A. PubMed ID: 10155090
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.